The phrase "a given venture" is correct and usable in written English.
It can be used to refer to a specific project or undertaking that is being discussed or considered.
Example: "In evaluating the risks associated with a given venture, it is essential to conduct thorough market research."
Alternatives: "a specific project" or "a particular undertaking".
Under the assumed risk rule, the defendant may argue that the plaintiff has assumed the risk of loss in entering into a given venture and understands the risks.
For example, a businessman may estimate the likelihood that a given venture could fail by recalling difficulties that his associates had encountered in the marketplace, rather than by relying on all the data available to him about the venture; the experiences most familiar to him can bias his assessment of the chances for success.
But at the end of the day, a whitepaper is just a promise to consumers about a given venture.
Evaluating the potential impact of a given venture requires a level of expertise that takes years to acquire.
Criteria based on valuation, metrics, events and time are not mutually exclusive, and can be combined in a variety of ways to construct the most appropriate vesting formula for a given venture.
As is true in many businesses, it is often the experienced business person who is successful at a given venture while a person with an extensive background in an area fails.
That, in turn, has given venture capitalists the incentive to invest in start-ups, and some of them are hiring.
He feels, however, that the time and costs added by preparing an investment for public listing has given some venture investors "less incentive to stay involved after an offering"–giving venture investors more impetus to hit the road and look for new companies.
We need a big kickoff IPO, because it gives venture capitalists a green light to begin serious investing again.
Ms. Bristol had just left a doctorate program in medieval English literature at the University of Texas to give venture capital a try.
These deals by large pharmaceutical firms, which recognized that their own research was inadequate and their drug pipelines were collapsing, gave venture capitalists a highly profitable way to cash out of their investments in biotech startups long before the fledgling companies had to deal with the expense and difficulty of scaling up or commercializing their technologies.
